(Q40487647)

English

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab

scientific article published in December 2004

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

21 September 2017

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab (English)

1 reference

Europe PubMed Central

21 September 2017

apoptotic process

0 references

author name string

Jeyanthi Ramanarayanan

1

1 reference

Europe PubMed Central

21 September 2017

Francisco J Hernandez-Ilizaliturri

2

1 reference

Europe PubMed Central

21 September 2017

Asher Chanan-Khan

3

1 reference

Europe PubMed Central

21 September 2017

Myron S Czuczman

4

1 reference

Europe PubMed Central

21 September 2017

language of work or name

0 references

publication date

1 December 2004

1 reference

Europe PubMed Central

21 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

21 September 2017

127

1 reference

Europe PubMed Central

21 September 2017

5

1 reference

Europe PubMed Central

21 September 2017

519-530

1 reference

Europe PubMed Central

21 September 2017

Germinal center phenotype and bcl-2 expression combined with the International Prognostic Index improves patient risk stratification in diffuse large B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Phase I studies of ZD1839 in patients with common solid tumors

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Human Bcl-2 antisense therapy for lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Signaling antibodies in cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Complement activation determines the therapeutic activity of rituximab in vivo.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Cellular stress response and apoptosis in cancer therapy.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Rituximab: mechanism of action and resistance

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Defying death after DNA damage.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Cell cycle deregulation in B-cell lymphomas.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Apoptosis in lymphocytic leukemias and lymphomas

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Apoptotic induction in transformed follicular lymphoma cells by Bcl-2 downregulation.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

The role of rituximab and chemotherapy in aggressive B-cell lymphoma: a preliminary report of dose-adjusted EPOCH-R.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2004.05239.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2004.05239.X

1 reference

Europe PubMed Central

21 September 2017

1 reference

Europe PubMed Central

21 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40487647&oldid=1898110534"